Sexual functioning is an integral part of human life. Female sexual dysfunction (FSD)
adversely affects quality of life and general well-being. The Food and Drug Administration
recently approved flibanserin, for treatment of female hypoactive sexual desire disorder
(HSDD), regarded as the most common FSD, amid great controversy. A novel multifunctional
serotonin agonist and antagonist, flibanserin, has been shown to be efficacious in treating
HSDD but with a rather tenacious side effect profile. We review this interesting drug in its …